BRITISH JOURNAL OF CANCER, vol.118, no.3, pp.366-377, 2018 (SCI-Expanded)
Article / Article
BRITISH JOURNAL OF CANCER
Science Citation Index Expanded (SCI-EXPANDED)
MTOR, pancreatic cancer, therapeutic resistance, IN-VIVO, DUCTAL ADENOCARCINOMAS, FEEDBACK ACTIVATION, PRECLINICAL MODELS, CELL PLASTICITY, ONCOGENIC KRAS, LUNG-CANCER, TUMORIGENESIS, RESISTANCE, EGFR
Acibadem Mehmet Ali Aydinlar University Affiliated:
Background: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs further clarification.